IBRX vs LYEL
IBRX: ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to harness the immune system against cancer and infectious diseases. LYEL: Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility.
Side-by-side fundamentals
| Metric | IBRX | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.51 | $12.84 | |
| Market cap as of 2026-07-23 | $8.0B | $315M | |
| PEG as of 2026-07-23 | -0.21 | n/a | |
| Net margin as of 2026-07-23 | -606.1% | -794858.1% | IBRX higher |
| Gross margin as of 2026-07-23 | +99.3% | n/a | |
| Operating margin as of 2026-07-23 | -185.4% | -823341.9% | IBRX higher |
| ROE as of 2026-07-23 | -193.3% | -85.7% | LYEL higher |
| ROA as of 2026-07-23 | -165.2% | -66.4% | LYEL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +351.5% | -52.3% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | +678.6% | -92.5% | IBRX higher |
| Beta as of 2026-07-23 | 0.15 | -0.05 | |
| 1-year return as of 2026-07-22 close | +177.1% | +38.1% | IBRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.